{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-032658","form_type":"8-K","ticker":"TGTX","cik":"0001001316","company_name":"TG THERAPEUTICS, INC.","filed_at":"2025-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.451933+00:00","generated_at":"2026-05-17T00:48:27.844877+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"TG Therapeutics raises BRIUMVI revenue guidance to $585M, Q3 net income $390.9M","bullets":["Q3 2025 total revenue $161.7M, BRIUMVI US net revenue $152.9M up 84% YoY.","Raises FY2025 BRIUMVI US net revenue target to ~$585M (prior $570-575M) and global target to $600M.","Q3 net income $390.9M includes $365M non-recurring tax benefit; net income $3.9M in Q3 2024.","Completed $100M buyback (3.5M shares at avg $28.55); authorized new $100M repurchase program.","Phase 3 subcutaneous ublituximab enrollment commenced; ENHANCE trial for consolidated IV dosing fully enrolled."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-032658","json":"https://secwatch.observer/filing/0001437749-25-032658.json","markdown":"https://secwatch.observer/filing/0001437749-25-032658.md","text":"https://secwatch.observer/filing/0001437749-25-032658.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1001316/000143774925032658/0001437749-25-032658-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1001316/000143774925032658/tgtx20250909_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:48:27.844877+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}